Mereo BioPharma
MREO
47 hedge funds and large institutions have $205M invested in Mereo BioPharma in 2020 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 6 closing their positions.
438% more capital invested
Capital invested by funds: $38.1M → $205M (+$167M)
333% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 6
68% more funds holding
Funds holding: 28 → 47 (+19)
33% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 6
8.56% more ownership
Funds ownership: 4.57% → 13.13% (+8.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$15.1M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$10.3M |
| 3 |
SCM
Suvretta Capital Management
New York
|
+$6.89M |
| 4 |
BC
Boxer Capital
San Diego,
California
|
+$5.5M |
| 5 |
Alkeon Capital Management
New York
|
+$4.85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$5.01M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$745K |
| 3 |
MWNA
Marshall Wace North America
New York
|
-$467K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$301K |
| 5 |
JG
Jefferies Group
New York
|
-$236K |
MREO Hedge Fund Activity: Q4 2020 in Review
47 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Mereo BioPharma (MREO) for Q4 2020, worth a combined $205M — up 438% from $38.1M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new MREO positions and 6 closed out — a net gain of 20 holders — while 8 added to existing stakes and 6 trimmed.
The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $15.1M. The largest seller was Vivo Capital, cutting an estimated $5.01M.
- 47 institutional investors held Mereo BioPharma (MREO) as of Q4 2020, up from 28 in Q3 2020.
- Funds reported $205M of Mereo BioPharma stock for Q4 2020, up 438% quarter-over-quarter.
- 26 funds opened new Mereo BioPharma positions in Q4 2020 and 6 closed out, a net change of +20 holders.
- The largest Mereo BioPharma buyer in Q4 2020 was Baker Bros. Advisors, an estimated $15.1M added.
- The largest Mereo BioPharma seller in Q4 2020 was Vivo Capital, an estimated $5.01M sold.
Based on aggregated 13F filings for Q4 2020.